Table of Contents

Total Page:16

File Type:pdf, Size:1020Kb

Table of Contents OCTOBER 2015 • VOLUME 59 • NO. 10 TABLE OF CONTENTS MINIREVIEWS Carbapenemase-Producing Klebsiella pneumoniae, a Key Johann D. D. Pitout, Patrice 5873–5884 Pathogen Set for Global Nosocomial Dominance Nordmann, Laurent Poirel Potential Targets for Antifungal Drug Discovery Based on Xiuyun Li, Yinglong Hou, Longtao Yue, 5885–5891 Growth and Virulence in Candida albicans Shuyuan Liu, Juan Du, Shujuan Sun Addressing Therapeutic Options for Ebola Virus Infection in Azizul Haque, Didier Hober, Joel 5892–5902 Current and Future Outbreaks Blondiaux CHALLENGING CLINICAL CASES IN ANTIMICROBIAL RESISTANCE Successful Treatment of Carbapenemase-Producing Pandrug- Jose F. Camargo, Jacques Simkins, 5903–5908 Resistant Klebsiella pneumoniae Bacteremia Thiago Beduschi, Akin Tekin, Laura Aragon, Armando Pérez-Cardona, Clara E. Prado, Michele I. Morris, Lilian M. Abbo, Rafael Cantón (Commentator) MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS Garcinia xanthochymus Benzophenones Promote Hyphal Desmond N. Jackson, Lin Yang, 6032–6038 Apoptosis and Potentiate Activity of Fluconazole against ShiBiao Wu, Edward J. Kennelly, Candida albicans Biofilms Peter N. Lipke Differential Effects of Penicillin Binding Protein Deletion on the George Sakoulas, Monika 6132–6139 Susceptibility of Enterococcus faecium to Cationic Peptide Kumaraswamy, Poochit Nonejuie, Antibiotics Brian J. Werth, Micahel J. Rybak, Joseph Pogliano, Louis B. Rice, Victor Nizet Subinhibitory Doses of Aminoglycoside Antibiotics Induce Sheng-Hui Tsai, Hsin-Chih Lai, 6161–6169 Changes in the Phenotype of Mycobacterium abscessus Shiau-Ting Hu New Insights Regarding Yeast Survival following Exposure to Rita Teixeira-Santos, Elisabete Ricardo, 6181–6187 Liposomal Amphotericin B Susana Gomes Guerreiro, Sofia Costa-de-Oliveira, Acácio Gonçalves Rodrigues, Cidália Pina-Vaz The Glucose Transporter PfHT1 Is an Antimalarial Target of the Thomas E. Kraft, Christopher 6203–6209 HIV Protease Inhibitor Lopinavir Armstrong, Monique R. Heitmeier, Audrey R. Odom, Paul W. Hruz Key Residues of Outer Membrane Protein OprI Involved in Ting-Wei Chang, Chiu-Feng Wang, 6210–6222 Hexamer Formation and Bacterial Susceptibility to Cationic Hsin-Jye Huang, Iren Wang, Shang-Te Antimicrobial Peptides Danny Hsu, You-Di Liao An Antifungal Benzimidazole Derivative Inhibits Ergosterol Petra Keller, Christoph Müller, Isabel 6296–6307 Biosynthesis and Reveals Novel Sterols Engelhardt, Ekkehard Hiller, Karin Lemuth, Holger Eickhoff, Karl-Heinz Wiesmüller, Anke Burger-Kentischer, Franz Bracher, Steffen Rupp Elevated Expression of GlpT and UhpT via FNR Activation Kumiko Kurabayashi, Koichi 6352–6360 Contributes to Increased Fosfomycin Susceptibility in Tanimoto, Shinobu Fueki, Haruyoshi Escherichia coli under Anaerobic Conditions Tomita, Hidetada Hirakawa Copper(II)-Bis(Thiosemicarbazonato) Complexes as Karrera Y. Djoko, Maira M. Goytia, 6444–6453 Antibacterial Agents: Insights into Their Mode of Action and Paul S. Donnelly, Mark A. Schembri, Potential as Therapeutics William M. Shafer, Alastair G. McEwan Instructions to Authors are available at http://journalitas.asm.org/t/46519. Continued on following page Continued from preceding page OCTOBER 2015 • VOLUME 59 • NUMBER 10 Antibacterial Action of Nitric Oxide-Releasing Chitosan Katelyn P. Reighard, Mark H. 6506–6513 Oligosaccharides against Pseudomonas aeruginosa under Schoenfisch Aerobic and Anaerobic Conditions MECHANISMS OF RESISTANCE Caspofungin Treatment of Aspergillus fumigatus Results in Louise A. Walker, Keunsook K. Lee, 5932–5941 ChsG-Dependent Upregulation of Chitin Synthesis and the Carol A. Munro, Neil A. R. Gow Formation of Chitin-Rich Microcolonies Multidrug Transporters and Alterations in Sterol Biosynthesis Elizabeth L. Berkow, Kayihura 5942–5950 Contribute to Azole Antifungal Resistance in Manigaba, Josie E. Parker, Katherine S. Candida parapsilosis Barker, Stephen L. Kelly, P. David Rogers Phylogeny and Comparative Genomics Unveil Independent Teresa G. Ribeiro, Ângela Novais, 5951–5958 Diversification Trajectories of qnrB and Genetic Platforms Raquel Branquinho, Elisabete within Particular Citrobacter Species Machado, Luísa Peixe Can Plazomicin Alone or in Combination Be a Therapeutic Cristina García-Salguero, Iciar 5959–5966 Option against Carbapenem-Resistant Rodríguez-Avial, Juan J. Picazo, Esther Acinetobacter baumannii? Culebras Residues Distal to the Active Site Contribute to Enhanced Dandan He, Jiachi Chiou, Zhenling 5976–5983 Catalytic Activity of Variant and Hybrid ␤-Lactamases Derived Zeng, Lanping Liu, Xiaojie Chen, Li from CTX-M-14 and CTX-M-15 Zeng, Edward Wai Chi Chan, Jian-Hua Liu, Sheng Chen Influence of the yjiL-mdtM Gene Cluster on the Antibacterial Andor Krizsan, Daniel Knappe, Ralf 5992–5998 Activity of Proline-Rich Antimicrobial Peptides Overcoming Hoffmann Escherichia coli Resistance Induced by the Missing SbmA Transporter System Genomic and Functional Portrait of a Highly Virulent, Amit Ranjan, Sabiha Shaik, Arif 6087–6095 CTX-M-15-Producing H30-Rx Subclone of Escherichia coli Hussain, Nishant Nandanwar, Torsten Sequence Type 131 Semmler, Savita Jadhav, Lothar H. Wieler, Niyaz Ahmed Delicate Metabolic Control and Coordinated Stress Response Peng Li, Chaminda J. Seneviratne, 6101–6112 Critically Determine Antifungal Tolerance of Candida albicans Emanuele Alpi, Juan A. Vizcaino, Lijian Biofilm Persisters Jin Antimicrobial Susceptibility and SOS-Dependent Increase in Jenny Yang, Thirunavukkarasu 6195–6202 Mutation Frequency Are Impacted by Escherichia coli Annamalai, Bokun Cheng, Srikanth Topoisomerase I C-Terminal Point Mutation Banda, Rakhi Tyagi, Yuk-Ching Tse-Dinh Modulation of ccrAB Expression and SCCmec Excision by an Shijie Zhang, Ronghua Ma, Xiaoyu Liu, 6223–6232 Inverted Repeat Element and SarS in Methicillin-Resistant Xu Zhang, Baolin Sun Staphylococcus aureus Mutations in ␤-Lactamase AmpC Increase Resistance of M. Berrazeg, K. Jeannot, Véronique 6248–6255 Pseudomonas aeruginosa Isolates to Antipseudomonal Yvette Ntsogo Enguéné, I. Broutin, S. Cephalosporins Loeffert, D. Fournier, P. Plésiat Detection of a New cfr-Like Gene, cfr(B), in Enterococcus Lalitagauri M. Deshpande, Deborah S. 6256–6261 faecium Isolates Recovered from Human Specimens in the Ashcraft, Heather P. Kahn, George United States as Part of the SENTRY Antimicrobial Surveillance Pankey, Ronald N. Jones, David J. Program Farrell, Rodrigo E. Mendes The Human Gut Microbiome as a Transporter of Antibiotic Johan Bengtsson-Palme, Martin 6551–6560 Resistance Genes between Continents Angelin, Mikael Huss, Sanela Kjellqvist, Erik Kristiansson, Helena Palmgren, D. G. Joakim Larsson, Anders Johansson Continued on following page Continued from preceding page OCTOBER 2015 • VOLUME 59 • NUMBER 10 Candida parapsilosis Resistance to Fluconazole: Molecular Ana Carolina R. Souza, Beth Burgwyn 6581–6587 Mechanisms and In Vivo Impact in Infected Galleria mellonella Fuchs, Henrique M. S. Pinhati, Larvae Ricardo A. Siqueira, Ferry Hagen, Jacques F. Meis, Eleftherios Mylonakis, Arnaldo L. Colombo IncA/C Plasmid Carrying blaNDM-1, blaCMY-16, and fosA3 in a L. Villa, B. Guerra, S. Schmoger, J. 6597–6600 Salmonella enterica Serovar Corvallis Strain Isolated from a Fischer, R. Helmuth, Z. Zong, A. Migratory Wild Bird in Germany García-Fernández, A. Carattoli Emergence of Extensively Drug-Resistant Proteus mirabilis Shangshang Qin, Hui Qi, Qijing Zhang, 6601–6604 Harboring a Conjugative NDM-1 Plasmid and a Novel Di Zhao, Zhen-Zhen Liu, Hao Tian, Salmonella Genomic Island 1 Variant, SGI1-Z Lijuan Xu, Hui Xu, Mengmeng Zhou, Xianju Feng, Hong-Min Liu A Plasmid Bearing the blaCTX-M-15 Gene and Phage P1-Like Juyoun Shin, Kwan Soo Ko 6608–6610 Sequences from a Sequence Type 11 Klebsiella pneumoniae Isolate A Novel Y319H Substitution in CYP51C Associated with Azole R. A. Paul, S. M. Rudramurthy, J. F. 6615–6619 Resistance in Aspergillus flavus Meis, J. W. Mouton, A. Chakrabarti Characterization of a Novel Putative Xer-Dependent Integrative Alberto Antonelli, Marco Maria 6620–6624 Mobile Element Carrying the blaNMC-A Carbapenemase Gene, D’Andrea, Vincenzo Di Pilato, Bruno Inserted into the Chromosome of Members of the Enterobacter Viaggi, Francesca Torricelli, Gian Maria cloacae Complex Rossolini Characterization of an Enterobacter cloacae Strain Producing Wenjing Wu, Yu Feng, Alessandra 6625–6628 both KPC and NDM Carbapenemases by Whole-Genome Carattoli, Zhiyong Zong Sequencing Fluconazole and Voriconazole Resistance in Candida Joana Branco, Ana P. Silva, Raquel M. 6629–6633 parapsilosis Is Conferred by Gain-of-Function Mutations in Silva, Ana Silva-Dias, Cidália Pina-Vaz, MRR1 Transcription Factor Gene Geraldine Butler, Acácio G. Rodrigues, Isabel M. Miranda Constitutive and Inducible Expression of the rRNA Methylase Fengru Deng, Jianzhong Shen, Maojun 6661–6664 Gene erm(B) in Campylobacter Zhang, Congming Wu, Qijing Zhang, Yang Wang SUSCEPTIBILITY Antimicrobial Activity of Fosfomycin-Tobramycin María Díez-Aguilar, María Isabel 6039–6045 Combination against Pseudomonas aeruginosa Isolates Assessed Morosini, Ana P. Tedim, Irene by Time-Kill Assays and Mutant Prevention Concentrations Rodríguez, Zerrin Aktas¸, Rafael Cantón Potent Ex Vivo Activity of Naphthoquine and Methylene Blue Grennady Wirjanata, Boni F. Sebayang, 6117–6124 against Drug-Resistant Clinical Isolates of Plasmodium Ferryanto Chalfein, Prayoga, Irene falciparum and Plasmodium vivax Handayuni, Leily Trianty, Enny Kenangalem, Rintis Noviyanti, Brice Campo, Jeanne Rini Poespoprodjo, Jörg J. Möhrle, Ric N. Price, Jutta Marfurt The Oral
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub
    US 20150250896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub. Date: Sep. 10, 2015 (54) HYDROPHILIC LINKERS AND THEIR USES Publication Classification FOR CONUGATION OF DRUGS TO A CELL (51) Int. Cl BNDING MOLECULES A647/48 (2006.01) (71) Applicant: Yongxin R. ZHAO, Henan (CN) Ek E. 30.8 C07D 207/216 (2006.01) (72) Inventor: R. Yongxin Zhao, Lexington, MA (US) C07D 40/12 (2006.01) C07F 9/30 (2006.01) C07F 9/572 (2006.01) (73) Assignee: Hangzhou DAC Biotech Co., Ltd., (52) U.S. Cl. Hangzhou City, ZJ (CN) CPC ........... A61K47/48715 (2013.01); C07F 9/301 (2013.01); C07F 9/65583 (2013.01); C07F (21) Appl. No.: 14/432,073 9/5721 (2013.01); C07D 207/46 (2013.01); C07D 401/12 (2013.01); A61 K3I/454 (22) PCT Filed: Nov. 24, 2012 (2013.01) (86). PCT No.: PCT/B2O12/0567OO Cell(57) binding- agent-drugABSTRACT conjugates comprising hydrophilic- S371 (c)(1), linkers, and methods of using Such linkers and conjugates are (2) Date: Mar. 27, 2015 provided. Patent Application Publication Sep. 10, 2015 Sheet 1 of 23 US 2015/0250896 A1 O HMDS OSiMe 2n O Br H-B-H HPC 3 2 COOEt essiop-\5. E B to NH 120 °C, 2h OsiMe3 J 50 °C, 2h eSiO OEt 120 oC, sh 1 2 3. 42% from 1 Bra-11a1'oet - Brn 11-1 or a 1-1 or ÓH 140 °C ÓEt ÓEt 4 5 6 - --Messio. 8 B1a-Br aus 20 cc, hP-1}^-'ot Br1-Y.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Use of the 4-Hydroxy-Triazole Moiety As a Bioisosteric Tool in the Development of Selective Ligands for Subtypes AMPA Receptor
    AperTO - Archivio Istituzionale Open Access dell'Università di Torino Use of the 4-hydroxy-triazole moiety as a bioisosteric tool in the development of selective ligands for subtypes AMPA receptor This is the author's manuscript Original Citation: Availability: This version is available http://hdl.handle.net/2318/1721210 since 2020-01-03T11:23:39Z Terms of use: Open Access Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law. (Article begins on next page) 09 October 2021 6th EFMC Young Medicinal Chemist Symposium September 5-6, 2019 | Athens, Greece Book of Abstracts YMCS19-BoA-Cover.indd 1 30/07/19 09:13 Organising Committees Chairman Dr Emmanouil FOUSTERIS (University of Patras, Patras, Greece) Members Dr David ALKER (David Alker Associates, Birchington, United Kingdom) Prof. Dennis GILLINGHAM (University of Basel, Basel, Switzerland) Dr Kristina GONCHARENKO (SpiroChem AG, Basel, Switzerland) Dr Cassandra LEE FLEMING (University of Gothenburg, Gothenburg, Sweden) Mr Brieuc MATAGNE (LD Organisation, Louvain-la-Neuve, Belgium) Dr Eleni PONTIKI (Aristotele University of Thessaloniki, Thessaloniki, Greece) Dr Matthew TOZER (Consultant, Cambridge, United Kingdom) Prof. Grigorios ZOIDIS (University of Athens, Athens, Greece) Content Welcome 2 Sponsors 3 Programme 5 Keynote Lectures 13 Oral Communications 19 Flash Poster Presentations 39 Posters Presentations 41 List of abstracts 153 List of participants 161 1 Welcome Dear participant, On behalf of the European Federation for Medicinal Chemistry (EFMC) and the Organising Committee, we warmly welcome you to Athens for the 6th edition of the EFMC Young Medicinal Chemist Symposium (EFMC-YMCS).
    [Show full text]
  • Informe Mensual De Producción Científica Del
    Instituto de Investigación Sanitaria Gregorio Marañón Listado de publicaciones por áreas y grupos de investigación JUNIO 2021 Nº FI ÁREA 1: INGENIERÍA BIOMÉDICA 1.01 Aplicaciones tecnológicas avanzadas y salud humana 2 5,016 1.02 Tratamiento de la señal 1 3,036 ÁREA 2: ENFERMEDADES CARDIOVASCULARES 2.01 Historia natural de la enfermedad cardiaca 11 57,049 2.03 Electrofisiología cardiaca celular 1 4,642 2.05 Cardiología y trasplante cardiaco infantil 3 8,838 2.06 Lípidos sanguíneos y riesgo cardiovascular 4 11,127 2.07 Enfermedad cerebrovascular aguda. Ictus 2 4,981 ÁREA 3: NEUROCIENCIA Y SALUD MENTAL 3.01 Bases neurobiológicas y psicológicas de los trastornos mentales. Trastornos del neurodesarrollo 8 71,342 3.03B Enfermedades Neurológicas 7 18,402 ÁREA 4: MICROBIOLOGÍA CLÍNICA, ENFERMEDADES INFECCIOSAS Y SIDA 4.01 Enfermedades infecciosas 8 45,759 4.02 Aspectos clínicos y epidemiológicos del VIH y condiciones asociadas 6 41,777 ÁREA 5: PATALOGÍA DEL SISTEMA INMUNE 5.01 Fisiopatología e investigación clínica de las enfermedades de base inmunológica e inflamatoria crónicas 4 11,686 5.02 Biología molecular del VIH 2 9,993 5.03 Enfermedades sistémicas de base autoinmune 4 16,730 5.05 Patogenia de la respuesta inmunoalérgica 1 7,574 5.06 Regulación y Homeostasis Inmune en Patologías relacionadas con el Sistema Inmunológico 1 4,717 5.07 Infecciones en la población pediátrica 6 16,314 ÁREA 6: ONCOLOGÍA TRASLACIONAL 6.01 Oncología interdisciplinar y bio-tecnológica 2 7,608 6.02 Oncología médica traslacional y terapia individualizada del cáncer 7 116,801 6.03 Genética y clínica de las neoplasias hematológicas y el trasplante hematopoyético 8 55,097 6.04 Oncología quirúrgica 1 1,354 ÁREA 7: PATALOGÍA DE GRANDES SISTEMAS Y TRASPLANTE DE ÓRGANOS 7.01 Inflamación y daño vascular en la Enfermedad Renal Crónica, Diálisis y Trasplante Renal.
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2015/0284416 Al Zhao (43) Pub
    US 20150284416A1 US 20150284416A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2015/0284416 Al Zhao (43) Pub. Date: Oct. 8,2015 (54) NOVEL LINKERS LOR CONJUGATION OL A61K47/48 (2006.01) CELL-BINDING MOLECULES C07K16/32 (2006.01) C07F 9/572 (2006.01) (71) Applicant: Robert Yongxin Zhao, Lexington, MA (US) A61K 31/537 (2006.01) (52) U.S. Cl. (72) Inventor: Robert Yongxin Zhao, Lexington, MA CPC ...........C07F 9/65583 (2013.01); C07F 9/5721 (US) (2013.01); A61K31/537 (2013.01); A61K (73) Assignee: SUZHOU M-CONJ BIOTECH CO., 47/48715 (2013.01); C07K16/32 (2013.01); LTD, Suzhou City (CN) A61K 47/48561 (2013.01 ),A61K 38/05 (2013.01) (21) Appl. No.: 14/740,403 (22) Filed: Jun. 16, 2015 (57) ABSTRACT Publication Classiflcation (51) Int. Cl. Cell binding agent-drug conjugates comprising hydrophilic C07F 9/6558 (2006.01) linkers, and methods of using such linkers and conjugates are A61K38/05 (2006.01) provided. PatentApplication Publication Oct. 8, 2015 Sheet I of 18 US 2015/0284416 Al FIGURES p 0 ° Λ O=PG3 H M /v. A N-VNH2 (Tjn-Vn-II-Ci ho^^nh, (f\-vΝ-Ρ-N ν^'ίOH -78°C, THF 1 H C' Cl --------2—W THO 4 O I Et3N η O O Q NllSZEDtC jf^N -P-NyVjlS0^ N^S I). Drug-SH DMA V HO “ . 2). mAb— (NH2)11 O OPCi3^ I n-vnh2 HO NH2 C' -78°C, THF I). Drug-SH 2). UiAb-(NH2)n 0. KJ kj ■Nj1^—1 Drug-NH2 (T\'VN'v^'"(LNn^-A>SzuV" Dri|8 dr & “V- P Figure I.
    [Show full text]
  • September 5-6, 2019 | Athens, Greece Book of Abstracts
    6th EFMC Young Medicinal Chemist Symposium September 5-6, 2019 | Athens, Greece Book of Abstracts YMCS19-BoA-Cover.indd 1 30/07/19 09:13 Organising Committees Chairman Dr Emmanouil FOUSTERIS (University of Patras, Patras, Greece) Members Dr David ALKER (David Alker Associates, Birchington, United Kingdom) Prof. Dennis GILLINGHAM (University of Basel, Basel, Switzerland) Dr Kristina GONCHARENKO (SpiroChem AG, Basel, Switzerland) Dr Cassandra LEE FLEMING (University of Gothenburg, Gothenburg, Sweden) Mr Brieuc MATAGNE (LD Organisation, Louvain-la-Neuve, Belgium) Dr Eleni PONTIKI (Aristotele University of Thessaloniki, Thessaloniki, Greece) Dr Matthew TOZER (Consultant, Cambridge, United Kingdom) Prof. Grigorios ZOIDIS (University of Athens, Athens, Greece) Content Welcome 2 Sponsors 3 Programme 5 Keynote Lectures 13 Oral Communications 19 Flash Poster Presentations 39 Posters Presentations 41 List of abstracts 153 List of participants 161 1 Welcome Dear participant, On behalf of the European Federation for Medicinal Chemistry (EFMC) and the Organising Committee, we warmly welcome you to Athens for the 6th edition of the EFMC Young Medicinal Chemist Symposium (EFMC-YMCS). Since the first edition of the EFMC-YMCS in 2014, the symposium has gone from strength to strength with increased participation from EFMC-National Adhering Organisations, and it is now firmly established as the premier forum in Europe for young Medicinal Chemistry and Chemical Biology researchers to promote their science. Our principal aims are: • Creating a network of young European investigators in Medicinal Chemistry and Chemical Biology • Stimulating young European investigators to share their scientific work with peers, and inspiring them to become leaders in their field • Creating competition, excellence and European Champions in Medicinal Chemistry and Chemical Biology This year, more than 170 scientists from 30 nations will gather in Athens for the latest edition.
    [Show full text]
  • Download the 2017-18 Annual Report
    Molecular Biology Institute ANNUAL REPORT 2017-2018 (310) 825-1018 mbi.ucla.edu UCLA Boyer Hall [email protected] MOLECULAR BIOLOGY INSTITUTE REMEMBERING PAUL BOYER MBI DIRECTOR’S REPORT 1 MBI COMMITTEES 3 MBI ADMINISTRATIVE SUPPORT STAFF ACTIVITIES Administrative Services 4 Building Management 5 MBI PROGRAMS & EVENTS The David S. Sigman Memorial Lectureship & Symposium 7 The Audree Fowler Fellows in Protein Science 8 The Jules Brenner Achievement Fellowship in Molecular Biology 9 Boyer/Parvin Postdoctoral Research Awards 10 Thursday Seminar Series 11 MBI Interdisciplinary Faculty Seminars 14 MBI Annual Retreat & Research Conference 18 Biotechnology Edge Workshop 16 Focus on Imaging Workshop 17 Mouse Genome Informatics Workshop 18 MBI FACULTY RESEARCH & PROFESSIONAL ACTIVITIES Newly Appointed Members 19 Honors & Professional Awards 22 Service on UCLA Committees 23 Service on External Committees 27 Patents Issued 32 Visiting Faculty & Scholars 33 MBI PARTNERS IN BOYER HALL Institute for Quantitative & Computational Biology (QCBio) 35 The QCBio Collaboratory 35 UCLA-DOE Institute 35 Fermentation Core Facility 36 GRADUATE PROGRAMS Molecular Biology Interdepartmental Ph.D. Program (MBIDP) 37 Whitcome Pre-doctoral Training Program 54 MEMBER PUBLICATIONS MBI Faculty Publications 55 PAUL D. BOYER 1918 - 2018 REMEMBERING WITH GRATITUDE PAUL D. BOYER 1918 - 2018 Dear Colleagues, This year will be forever memorable in the history of our Institute because it marks the passing of our beloved Paul Boyer. His many scientific and academic accomplishments have been highlighted in several journals and it has been wonderful to hear so many colleagues speak about how much Dr. Boyer meant to them. We are grateful for his vision, his collegiality, his commitment to scientific excellence and his optimistic spirit, all of which became part of the culture of our institute.
    [Show full text]
  • WO 2013/167743 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/167743 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/18 (2006.01) A61K 31/708 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/522 (2006.01) A61K 45/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/675 (2006.01) A61P 29/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 31/7068 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (21) International Application Number: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, PCT/EP2013/059752 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (22) International Filing Date: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 10 May 2013 (10.05.2013) ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 12167771 .0 11 May 2012 ( 11.05.2012) EP TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: AKRON MOLECULES GMBH [AT/AT]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Helmut-Qualtinger-Gasse 2, A-1030 Vienna (AT).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0346380 A1 Stenler Et Al
    US 2016.0346.380A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346380 A1 Stenler et al. (43) Pub. Date: Dec. 1, 2016 (54) T20 CONSTRUCTS FOR ANTI-HIV (HUMAN (52) U.S. Cl. IMMUNODEFICIENCY VIRUS) THERAPY CPC ............... A61K 39/21 (2013.01); A61K 45/06 AND/OR VACCINES (2013.01); A61K 39/42 (2013.01); A61 K (71) Applicant: Immunomedics, Inc., Morris Plains, NJ 2039/53 (2013.01) (US) (57) ABSTRACT (72) Inventors: Sofia Stenler, Stockholm (SE); Britta Wahren, Stockholm (SE): Chien-Hsing The present invention concerns methods and compositions SS SSA S.sid for treatment of HIV infection using a T20 expression 9, s vector, such as that shown in SEQ ID NO:1 or SEQ ID (21) Appl. No.: 15/164,437 NO:3. The T20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of (22) Filed: May 25, 2016 dendritic cells to induce a host immune response to HIV. Related U.S. Application Data localized transfection in vivo in a gene therapy approach to (60) Provisional application No. 62/167,404, filed on May provide longer term delivery of T20, or in vitro production 28, 2015 s w is of T20 peptide. The T20 may be secreted into the circulation s to act as a fusion inhibitor of HIV infection, or may induce Publication Classification an endogenous immune response to HIV or HIV-infected (51) Int. Cl cells. Alternatively, a DDD peptide may be incorporated in A. iK 39/21 (2006.01) a fusion protein comprising T20 or another antigenic protein A6 IK 39/42 (2006.01) or peptide to enhance the immune response to the protein or A6 IK 45/06 (2006.01) peptide.
    [Show full text]
  • Abstracts Bialystok 2019
    BOOK OF ABSTRACTS BIALYSTOK 2019 14th Bialystok International Medical Congress for Young Scientists Book of Abstracts Białystok 2019 1 BIALYSTOK 2019 © Copyright by Students’ Scientific Society of the Medical University of Bialystok, 2019 Wszystkie prawa zastrzeżone. Przedruk i reprodukcja w jakiejkolwiek postaci całości bądź części książki bez pisemnej zgody wydawcy są zabronione. Redaktor: Małgorzata Kowalska, Monika Oleksiuk, Bogumiła Szewczak, Sylwia Bajko Korekta: Anna Krętowska, Aleksandra Basaj Grafika: Marta Śleszyńska ISBN: 978-83-952075-0-1 Za treść i format poszczególnych streszczeń odpowiadają ich autorzy. STN UMB nie odpowiada za informacje podane w formularzach zgłoszeniowych (błędy w nazwiskach, tytułach etc.) 2 BIALYSTOK 2019 Dear Colleagues, It is a great pleasure for me to welcome the participants of the 14th Bialystok International Medical Congress (BIMC) from Poland, Lithuania, Belarus, Ukraine and Latvia who came to Bialystok in order to exchange scientific experience and have a good time for a few days in one of the most enjoyable cities of Poland. We are truly happy and privileged to welcome you at Medical University of Bialystok. This is thank to your continuous interest and kindness that BIMC has become one of the most vibrant congresses gathering hundreds of young scientists from different European countries. I wish to thank warmly the Organizing Committee of the 14th BIMC for their enormous dedication, contagious energy and numberless efforts they put into making this event so unique. Let me extend special thanks to all members of faculty of the Medical University of Bialystok who agreed to sacrifice their time in order to share their experience and scientific advice during numerous scientific sessions.
    [Show full text]
  • WO 2015/151078 A4 8 October 2015 (08.10.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/151078 A4 8 October 2015 (08.10.2015) P O P C T (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every C07F 9/6558 (2006.01) C07K 16/32 (2006.01) kind of regional protection available): ARIPO (BW, GH, A61K 38/05 (2006.01) C07F 9/572 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, A61K 47/48 (2006.01) A61K 31/537 (2006.01) TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (21) Number: International Application DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, PCT/IB20 15/054521 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (22) International Filing Date: SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 15 June 2015 (15.06.2015) GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17 : (26) Publication Language: English — as to the identity of the inventor (Rule 4.1 7(Ϊ)) — as to applicant's entitlement to apply for and be granted a (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD patent (Rule 4.1 7(H)) [CN/CN]; Room B2001-B2019, Building 2, No. 452 Six Street, Heda, Hangzhou City, Zhejiang Province, 310018 — of inventorship (Rule 4.17(iv)) (CN).
    [Show full text]
  • Us 2019 / 0127401 A1
    US 20190127401A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0127401 A1 ZHAO et al. (43 ) Pub . Date : May 2 , 2019 ( 54 ) CHARGED LINKERS AND THEIR USES FOR Publication Classification CONJUGATION (51 ) Int. Ci. CO7F 9 / 30 (2006 . 01 ) (71 ) Applicant : HANGZHOU DAC BIOTECH CO . , CO7F 9 /572 ( 2006 . 01 ) LTD ., Hangzhou ( CN ) C07F 9 /6558 ( 2006 .01 ) A61K 47/ 68 ( 2006 . 01 ) (72 ) Inventors : Robert Yongxin ZHAO , Hangzhou C07F 9 /6561 ( 2006 . 01 ) ( CN ) ; Xing LI, Hangzhou (CN ) ; CO7F 9 / 32 ( 2006 .01 ) Yuangyuang HUANG , Hangzhou A61K 38 /07 ( 2006 . 01 ) (CN ) ; Qingliang YANG , Hangzhou CO7F 9 /58 ( 2006 . 01) ( CN ) .) U . S . CI. CPC . C07F 9 / 301 ( 2013 .01 ) ; CO7F 9 / 58 ( 2013 .01 ) ; CO7F 9 /65583 ( 2013 .01 ) ; A61K (73 ) Assignee : HANGZHOU DAC BIOTECH CO ., 47/ 6817 ( 2017 .08 ) ; A61K 47 /6851 ( 2017 .08 ) ; LTD . , Hangzhou (CN ) A61K 47 /6811 ( 2017 .08 ) ; A61K 47 /6809 ( 2017 .08 ) ; A61K 47/ 6807 ( 2017 .08 ) ; A61K (21 ) Appl . No. : 16 / 228 , 437 47 /6803 (2017 .08 ) ; A61K 47 /6889 ( 2017 . 08 ) ; CO7F 9 /65616 (2013 .01 ) ; CO7F 9 /3211 ( 2013 . 01 ) ; CO7F 9 / 3217 ( 2013 .01 ) ; A61K ( 22 ) Filed : Dec. 20 , 2018 38 /07 ( 2013 . 01 ) ; C07F 9 / 302 ( 2013 . 01) ; C07F 9 / 6561 ( 2013 .01 ) ; C07F 9 /572 ( 2013 .01 ) Related U . S . Application Data (57 ) ABSTRACT (62 ) Division of application No . 15 / 118 , 726 , filed on Aug . Cell binding agent -drug conjugates comprising phosphinate 12 , 2016 , filed as application No . PCT/ CN2014 / based charged linkers and methods of using such linkers and 072769 on Feb .
    [Show full text]